Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients.
Macías M, García-Cortés Á, Torres M, Ancizu-Marckert J, Ignacio Pascual J, Díez-Caballero F, Enrique Robles J, Rosell D, Miñana B, Mateos B, Ajona D, Sánchez-Bayona R, Bedialauneta O, Chocarro S, Navarro A, Andueza MP, Gúrpide A, Luis Perez-Gracia J, Alegre E, González Á. Macías M, et al. Among authors: luis perez gracia j. Cytokine. 2021 May;141:155471. doi: 10.1016/j.cyto.2021.155471. Epub 2021 Feb 16. Cytokine. 2021. PMID: 33607398 Free article. Clinical Trial.
Cellular cytotoxicity is a form of immunogenic cell death.
Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I, Etxeberrria I, Bolaños E, Azpilikueta A, Garasa S, Casares N, Perez Gracia JL, Rodriguez-Ruiz ME, Berraondo P, Melero I. Minute L, et al. J Immunother Cancer. 2020 Mar;8(1):e000325. doi: 10.1136/jitc-2019-000325. J Immunother Cancer. 2020. PMID: 32217765 Free PMC article.
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, Nie X, Chen L, Guedan S, Sanamed MF, Perez Gracia JL, Melero I. Glez-Vaz J, et al. J Immunother Cancer. 2022 Mar;10(3):e003532. doi: 10.1136/jitc-2021-003532. J Immunother Cancer. 2022. PMID: 35236742 Free PMC article.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
García-Goñi M, Vázquez Gutiérrez B, Sanmamed MF, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, Chumbiauca E, Martín-Calvo N, Galofré JC. García-Goñi M, et al. Among authors: luis perez gracia j. Endocr Relat Cancer. 2024 Aug 8;31(10):e240064. doi: 10.1530/ERC-24-0064. Print 2024 Oct 1. Endocr Relat Cancer. 2024. PMID: 39013402